Implant design affects markers of bone resorption and formation in total hip replacement.
Concentrations of the bone resorption markers pyridinoline and deoxypyridinoline and the bone formation marker osteocalcin were measured in 24-h urine collections from 30 subjects who underwent unilateral total hip replacements for monoarticular symptomatic osteoarthrosis and 10 controls. The patient groups were divided based on the femoral implant type (cemented cobalt alloy stem, cementless porous coated cobalt alloy stem, and cementless porous coated titanium alloy stem). Urine collections were performed before surgery and then at 3, 6, 12, 24, and 36 months. There were significant changes over time in the three patient groups for pyridinoline, deoxypyridinoline, and the ratio of osteocalcin to deoxypyridinoline (p < or = 0.01), but the control group values did not change over time. The resorption markers tended to peak at 3 months and the osteocalcin to deoxypyridinoline ratio was more variable, having depressed values in the cementless cobalt alloy group and elevated values in the other two groups compared with baseline. The cementless cobalt alloy group had higher resorption marker levels than the cemented cobalt alloy group at 6, 12, 24, and 36 months and higher levels than the cementless titanium alloy group at all postoperative times (p < 0.05). The osteocalcin to deoxypyridinoline ratio was lower in the cementless cobalt alloy group than in the cemented cobalt alloy group at 3, 6, and 24 months and the cementless titanium alloy group at 6, 12, and 24 months (p < 0.05). For the cemented cobalt chrome group, the baseline-normalized resorption marker values at 3 months and 6 months were correlated with the severity of radiographically assessed bone loss at 36 months (0.749 < r < 0.840; p < 0.05). For the cementless titanium alloy group, baseline-normalized osteocalcin/ deoxypyridinoline ratios at 3 months and 6 months were related inversely to radiographic bone loss at 36 months (0.687 < r < 0.749; p < 0.05). Thus, body fluid markers of bone metabolism change after total hip replacement. In addition, the changes in the marker concentrations were sensitive to implant design and were correlated with subsequent stress-shielding-induced bone loss.
Qureshi
Abid A
AA
Virdi
Amarjit S
AS
Didonna
Michael L
ML
Jacobs
Joshua J
JJ
Masuda
Koichi
K
Paprosky
Wayne P
WP
Thonar
Eugene J M A
EJ
Sumner
Dale R
DR
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000497:Alloys; D000596:Amino Acids / Q000652:urine; D015415:Biomarkers / Q000652:urine; D001862:Bone Resorption / Q000209:etiology / Q000652:urine; D016022:Case-Control Studies; D003035:Cobalt; D005260:Female; D006622:Hip Prosthesis / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000601:surgery; D015675:Osteocalcin / Q000652:urine; D010012:Osteogenesis / Q000502:physiology; D011446:Prospective Studies; D011474:Prosthesis Design; D014025:Titanium
D000497:Alloys; D000596:Amino Acids; D015415:Biomarkers; D015675:Osteocalcin; D003035:Cobalt; C015484:pyridinoline; C036020:deoxypyridinoline; D014025:Titanium